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ABSTRACT 
(6)-Gingerol, a disease modifying anti-rheumatoid drug (DMARD) agent in the treatment of Rheumatoid Arthritis is a potent inhibitor of COX-1, 
COX-2 activity, inhibits PGE2 production. It also inhibits the production of TNF-α by blocking the cell associated conversion of TNF precursor to 
mature proteins thus, halting the proliferation of synovitis. (6)-Gingerol undergo extensive phase I metabolism & underlies low systemic 
exposure. The aim of the present study was to overcome these limitations and formulate and evaluate Ginger extract Solid Lipid Nanoparticles 
to improve bioavailability by enabling lymphatic uptake. (6)-Gingerol Solid Lipid Nanoparticles were prepared by melt emulsification-
homogenization method and the particle size, Zeta potential PDI and % entrapment efficiency was optimized using Box Behnken design. The 
optimized SLN were found to be 237nm in size, bearing -25.3mv zeta potential, 0.350 PDI and entrapment efficiency of 91.33%.  Ex vivo 
endocytic uptake studies (everted intestine method) revealed involvement of endocytic pathways in the uptake of Solid Lipid Nanoparticles 
from intestine. Thus underlining the utility of SLN for enhancement of uptake of (6)-Gingerol. 
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ABBREVIATIONS: DMARD- Disease Modifying Anti-Rheumatoid Drug, SLN-Solid ipid nanoparticles, EE -Entrapment efficiency. 
1. INTRODUCTION 
The traditional approach to treatment of rheumatoid 
arthritis (RA) is a combination of disease modifying anti 
rheumatoid drugs (DMARDs) and NSAIDs 1. Various agents 
such as chloroquine, 5fluoro uracil, sulfasalazine have been 
reported to have disease modifying properties1,2,3. However 
the toxicity of some of these agents leads us to look to 
phytochemicals which have DMARD like action, there are 
many medicinal plant extracts that have been shown to be 
effective in treating RA, e.g. aloe vera, ashwagandha, ginger, 
piperine 4. One such compound (6)-Gingerol(C17H26O4) is 
homologous phenolic ketones found in fresh ginger rhizome 
(Zingiber officinale Rosco) belonging to the family 
Zingiberaceae 8. 
(6)-Gingerol inhibits the production of TNF-α by blocking the 
cell associated conversion of TNF Precursor to mature 
proteins thus halting the proliferation of synovitis. Gingerol 
is a potent inhibitor of COX-1, COX-2 activity and inhibits 
PGE2 production thus decrease proliferation of inflammation 
and disease condition. (6)-Gingerol is given orally in a dose 
of 120mg//kg/day. The low solubility of (6)-Gingerol has led 
to its poor oral absorption and fast metabolism has hindered 
the clinical applications of the drug 5,6. Currently, gingerols 
are available as soft capsule formulation. It has been 
suggested that new therapeutic approaches should be 
directed at overcoming the issues relating to effective 
delivery, potential off-target effects, safety, toxicity, large-
scale production costs, and tissue specificity 5,6. 
To overcome these limitations, (6)-Gingerol has been 
formulated as SMEDDS and proliposomes which has resulted 
in improved bioavailability by 5-fold in vivo compared with 
free drug 5,6. Solid Lipid Nanoparticles (SLN) are colloidal 
drug carriers and have particle size ranging from 50nm to 
1000nm which have ability to enter lymphatic circulation 
when administered orally through Peyer’s patch 9,10,11. 
Hence formulation of (6)-Gingerol as lipid nanoparticles may 
be able to improve bioavailability by entry of particles 
through lymphatic route and also may allow the 
accumulation of SLN at inflamed site by passive diffusion 12. 
The present work attempts to incorporate ginger extract in 
SLN by using principal of design of experiment (DOE) and 
demonstrate its lymphatic uptake by ex vivo everted rat gut 
sac model. 
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2. MATERIAL AND METHODS: 
2.1. Materials 
Ginger extract was obtained as a gift sample from Natural 
Remedies (Bangalore, India). (6)-Gingerol Marker was 
purchased from Sigma-Aldrich life sciences (India), Glyceryl 
monostearate, Compritol 888 ATO, Emulcire 61 and Precirol 
ATO 5 were kind gifts from Gatefosse (France). All the other 
chemicals and reagents were procured from local sources. 
2.2 Methods 
2.2.1 Standard calibration curve of (6)-Gingerol by UV-
Visible Spectrophotometer 
Solution of (6)-Gingerol (10 µg/ml) was in concentration 
range of 5 to 30μg/ml were prepared with methanol. The 
absorbance of resulting solutions was measured at 282 nm 
using double beam UV-Visible Spectrophotometer 
(LABINDIA UV 3000) against methanol as blank 13. 
2.2.2 Selection of lipid using solubility parameter (  ) 
14,15: 
Difference in the solubility parameter of drug and various 
lipids was considered for selection of lipid. The solubility 
parameter was calculated on the basis of molecular structure 
of the drug and lipid. The Fedors group contribution method 
assigns specific values to different groups as well as bonds in 
molecular structure and so energy of vaporization (∆Eυ) and 
molar volume (Vm) values are specific for each group.The 
  for each molecular structure was calculated by using the 
formula given below (Eq 1), and then the difference between 
the Solubility parameter of drug and the lipid was noted14,15. 
  (      )0.5 
where, ∆Eυ -the energy of vaporization at a given 
temperature and  
Vm -the corresponding molar volume which is calculated 
from the known values of molecular weight and density. 
2.2.3 Selection of Surfactant System 16: 
Melt Emulsification-homogenisation method was used to 
prepare SLN18. A mixture of Ginger extract and Stearic acid 
was melted at 70C.  Aqueous phase was prepared by 
dissolving various surfactants into distilled water at 70C. 
Two phases were mixed at the same temperature followed 
by stirring under an over-head stirrer at 800rpm for 15 
minutes to obtain a uniform emulsion, which was further 
subjected to High Pressure Homogeniser at homogenisation 
Pressure 400 bars and 9 homogenization cycles. The 
resultant SLN was evaluated for particle size and PDI. The 
surfactant system was chosen depending upon the average 
diameter of the globules produced and Poly Dispersity Index 
(PDI) of the resultant emulsion upon employing the 
surfactant system. (Table 1). 
Table 1: Trial combinations of surfactant used for 
preparation of solid lipid nanoparticles. 
Batches Water Phase Surfactant (2%) 
T1 Sodium Lauryl Sulphate 
T2 Poloxamer 188 
T3 Tween 80 
 
 
2.2.4 Drug Excipient Compatibility Studies: 
Compatibility of Ginger extract with Stearic acid and Tween 
80 was checked in physical mixtures (1:1 ratio) stored at 
40oC for two weeks. Fourier transform- infrared 
spectroscopic analysis (FT-IR) was carried out in Shimadzu-
IR Spectrophotometer. Samples were dispersed in KBr and 
compressed into pellet by application of pressure. The 
scanning range was 4000-400 cm-1 and resolution was 1cm-1. 
2.2.5 Optimization and formulation of SLN containing 
ginger extract: 
A Box Behnken Design of 13 experimental runs was used to 
evaluate three variables at 3 levels viz.  Surfactant 
concentration, homogenization pressure, homogenization 
cycle in order to determine their effect on two responses 
percentage entrapment efficiency and particle size and their 
interaction therein. The layout of the experimental design is 
shown in table 2 and 3. 
 
Table 2: Design layout of box behnken design for optimization of solid lipid nanoparticles. 
Sr. No. Factors Responses 
1 Concentration of surfactant  
(Tween 80) (%) 
-1 0 +1 Percentage Entrapment Efficiency (%) 
2 Homogenization Pressure (Bar) -1 0 +1 Particle Size (nm) 
3 Homogenization Cycles (number) -1 0 +1  
 
Table 3: Translation of experimental conditions into physical units for preparation of  solid lipid nanoparticles 
containing ginger extract. 
Sr. No. Factor 1(A): Aqueous Phase 
Surfactant (Tween 80) (%) 
Factor2(B):Homogenizat
ion Pressure 
(Bar) 
Factor3(C):Homogenization 
Cycles 
(number) 
-1 0.5 400 6 
0 1 800 9 
+1 1.5 1200 12 
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2.2.6 Characterization of SLN containing ginger extract: 
2.2.6.1 Determination of Particle size 25: 
The particle size analysis of the prepared Solid Lipid 
Nanoparticle dispersions was performed using Malvern 
Zetasizer ZS 90 (Malvern Instruments, Worcestershire, UK), 
utilizing laser diffraction with beam length 2.40 mm, range 
lens of 300 RF mm, and at 14.4% obscuration. The sample 
was diluted with distilled water prior to the analysis. The 
mean diameter and the poly dispersity index of each batch 
were recorded. 
2.2.6.2 Determination of Entrapment Efficiency 25: 
The SLN dispersion was subjected to centrifugation at 
20,000 rpm (Make-Remi, Model-R4C ) for 15 minutes and 
the supernatant was analysed for unentrapped (6)-Gingerol 
spectrophotometrically at 282 nm using methanol as a 
solvent. EE was calculated according to the equation 2. 
   
 
                                   
                                                     
     
2.2.6.3 Determination of Zeta Potential: 
Zeta potential analysis was carried out using the additional 
electrode of Malveran Zetasizer that was used for particle 
size and PDI analysis. A sample of SLN was diluted with 
distilled water and subjected into disposable sizing cuvette 
for measurement at temperature of 25oC with setting of 
dispersant RI at 1.33 and dielectric constant of dispersant at 
78.5 in triplicates. 
2.2.6.4 Differential Scanning Calorimetry (DSC): 
Differential scanning calorimetry (DSC) studies were carried 
out on (6)-Gingerol, stearic acid and SLN containing ginger 
extract using Mettler Toledo DSC823 *e software (Columbia, 
USA). Samples were accurately weighed and heated in sealed 
aluminium pans at a rate 10°C/min between 25 - 200°C 
temperature rang under nitrogen atmosphere at flow rate of 
40ml/minute. Empty aluminium pan was used as a 
reference. 
2.2.7 Ex vivo endocytic uptake study 19: 
It has been seen that there are multiple methods reported 
for determination of uptake of lipid based nanoparticles 
from an intestine. In order to study the uptake of ginger 
extract SLN across rat intestine, endocytic uptake study 
using everted rat intestine model was done. Segments of 
small intestine of sacrificed rat were procured, cleaned and 
everted using a glass rod. One end of the intestinal segment 
was sealed using a silk suture, while from the other open 
end, 1 ml of phosphate buffer of pH 6.8 was added inside and 
sealed using silk suture. The resultant sac was further 
incubated in a dispersion containing SLN. (6)-Gingerol 
concentration in the phosphate buffer was estimated using 
UV method. 
The uptake mechanism of the SLN was evaluated by the 
intestinal cells in detail, everted gut sacs as described above 
were also incubated with specific endocytic inhibitors like 
chlorpromazine (concentration of 30 μg/ml) and nystatin 
(concentration of 45 μg/ml) at 37 °C for 30 mins and in (6)-
Gingerol-SLN dispersions at 4 °C. After 30mins of incubation 
the phosphate buffer from the intestinal sacs were carefully 
collected in test tubes and subjected to spectrophotometric 
analysis. 
3. RESULTS AND DISCUSSION 
3.1 Standard calibration curve of (6)-Gingerol by UV-
Visible Spectrophotometer 
Calibration curve of (6)-Gingerol was established at λmax 
282nm in methanol. The Beer’s law was obeyed between 
concentration range of 5-30μg/ml and the equation of line 
and R2 was found to be y=0.039x + 0.050and 0.996 
respectively (figure 1). 
 
Figure 1: Calibration curve of (6)-Gingerol 
3.2 Selection of Lipid Based on Solubility Parameter 14,15: 
The solubility parameter of a liquid δ, defined as the square 
root of the cohesive energy density is a quantity which, in 
conjunction with suitable theory, allows one to estimate 
several thermodynamic properties of solutions. The 
cohesive energy density itself is defined as the ratio of the 
energy of vaporization, ∆Eυ to the molar volume both 
referred to the same temperature. Solubility parameters are 
widely used to describe the cohesive forces within materials 
and have been used to describe many physical properties of 
a material and predict interactions between materials Table 
4. Fedors group contribution method of estimating solubility 
parameter is superior to Small’s method for two reasons: 
1) the contribution of a much larger number of functional 
groups can be evaluated, and 
2) the method requires only a knowledge of the structural 
formula of the compounds 15. 
 
Table 4: Solubility parameter of (6)-Gingerol and various lipids together with their differences. 
Sr. No. Drug/ Lipid Name Solubility Parameter (MPa1/2) Difference with (6)-
Gingerol (∆δ) 
1 Gingerol-6 24.34 --- 
2 Compritol 888 ATO 21.26 3.08 
3 GMS 18.66 5.68 
4 Precirol ATO 5 21.63 2.71 
5 Emulcire 61 19.27 5.07 
6 Stearic Acid 22.28 2.06 
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3.3 Selection of Surfactant System 16,24: 
SLN containing sodium lauryl Sulphate (SLS) produced 
substantially smaller particle size, but owing to the toxicity 
profile, high poly dispersity index and associated instability 
of the suspending property, it was eliminated as a choice. 
Other excipient such as Poloxamer 188 had smaller particle 
size and also low poly dispersity index due to its gelation 
property on storage it was not selected as surfactant for 
further experiments. Tween 80 resulted in particle size of 
299 nm and PDI of 0.350 and hence this was chosen for 
further studies Table 5.  
Tween 80 as a long chain surfactant provides aqueous phase 
stability to the emulsion formed thus leading to the 
formation of an emulsion system of which, low particle size 
and PDI is functional characteristics. 
 
Table 5: Represents various findings of different amalgamations of lipid and water based surfactant. 
Batches Solid Lipid 
Stearic acid(%) 
Water Phase Surfactant 
(Tween 80) (%) 
Mean *Particle 
Size (nm) 
*PDI Observation 
B1  
 
Stearic acid 
Sodium Lauryl Sulphate 347.30 0.328 Higher Particle Size 
B2 Poloxamer 188 384.37 0.280 Has Caused Gelation on storage   
B3 Tween 80 269.2 0.350 Stable on Storage 
*n=3 i.e. average of three readings 
3.4 Drug Excipient Compatibility Studies: 
The compatibility data of with potential formulation 
excipients studied by FT-IR spectroscopy is presented in 
Figure 2. The characteristic peaks of Ginger extract are 
retained. The peaks were observed at (3600 cm-1)- Aliphatic 
O-H stretch, (3100 cm-1)- Aromatic C-H Stretch,(896 cm-1)- 
Aliphatic C-O, (1680 cm-1)-C=O, (1670 cm-1)-C=C, (1315 cm-
1)-C-H Stretch, with only minor shifts in wave number thus 
suggesting that there is no interaction between the ginger 
extract and other excipients. Hence drug- excipients 
compatibility was established. 
 
  
Figure 2: FT-IR spectra of (A) Ginger extract, (B) Ginger extract +Stearic Acid, (C) Ginger extract + Tween 80 
 
3.5 Optimization and formulation of SLN containing 
ginger extract: 
Ginger extract SLN were prepared by melt emulsification 
Homogenization, it is a technique in which particles are 
forced through a specifically engineered homogenizing valve 
under high density fluid-dynamic energy condition. Ginger 
extract SLN and Blank SLN were prepared as per the 
experimental design and evaluated.  
The Box-Behnken design reduces number of experiments in 
a 3- Factor, 3-Levels experimental design from 27 to 13. 
Another advantage of the Box-Behnken design is that it does 
not contain combinations for which all factors are 
simultaneously screened at their highest or lowest levels.  
SELECTION OF LEVELS  
A) Selection of surfactant concentration: 
 It was observed that 0.5% concentration gives high particle 
size of 712 nm and when we increased the concentration of 
surfactant, particle size decreased upto 300.  Surfactant 
concentration above 1.5% solubilises drug in the micelles in 
the aqueous phase, leading to reduce entrapment efficiency. 
B) Selection of homogenization pressure: 
When the applied homogenization pressure was increased 
from 400-1200 bar, particle size slowly decreased from 
712nm to 287 nm. Homogenization pressure above 1200 bar 
leads to an increased particle size due to coalescence, this 
occurs because of the high kinetic energy of the particles 23. 
C) Selection of homogenization cycles: 
It was observed that as the no. of homogenization cycle 
increased, particle size was decreased. An increase in 
homogenization cycles above 12 resulted in increased 
particle size. This might be due to the high kinetic energy of 
small particles that show aggregation of particles 23.
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Table 6: Experimental run and responses for optimization of ginger extract solid lipid nanoparticles formula using 
box- behnken design. 
  Factor 1 Factor 2 Factor 3 Response 1 Response 2 
Std Run A:Surfactant 
conc 
B:Homogenization 
Pressure 
C:Homogenization 
Cycle 
Particle 
size 
Entrapment 
efficiency 
  % Bar Unit Nm % 
7 1 0.5 800 12 570 92.16 
10 2 1 1200 6 298 82.33 
4 3 1.5 1200 9 230 70 
5 4 0.5 800 6 584 92.25 
9 5 1 400 6 681 91.25 
6 6 1.5 800 6 469 80 
2 7 1.5 400 9 611 80.5 
12 8 0.5 1200 12 310 82.16 
3 9 1 1200 9 237 91.33 
11 10 1 400 12 659 90.58 
8 11 1.5 800 12 447 74.58 
13 12 1 800 9 510 89 
1 13 0.5 400 9 712 92.33 
 
3.6 Characterisation of SLN containing ginger extract: 
3.6.1 Determination of Particle Size: The particle size 
across the optimization runs was observed to range between 
230 to 712 nm. The particle size decreased commensurate 
with increasing surfactant concentration. 
Equation 3 for Particle Size:  
Particle Size= +510.00-51.13 A-191.00 B-8.63 C+7.75 AB-
2.00 AC+2.75 BC-2.75 A2-39.00 B2+10.25 C2 
The proposed model for particle size indicates that term A 
(conc of tween 80) decreases particle size, as tween 80 
forms a protective layer around the particle thus inhibits 
aggregation of particles, whereas term B (homogenization 
pressure) had most dominant effect which is due to 
homogenizing valve under high density fluid-dynamic energy 
conditions and term C (homogenization cycle) also 
contributed in decreasing particle size. All three factors are 
higher order term was seen to have linear relationship in 
reducing particle size. Similar effects were shown in figure 3, 
4 and 5. 
The interaction term AB i.e. as the surfactant concentration 
and homogenization pressure went on increasing it 
contributed to decrease the particle size. At low surfactant 
concentration the additional surface generated was not 
adequately protected by surfactant molecules and hence 
causing aggregation and larger particle size. 
According to interaction term AC the particle size was seen 
to decrease with the increase in the surfactant concentration, 
but the influence of homogenization cycle on particle size 
was not so dominant. 
The interaction term BC i.e. with the increase in the 
homogenization pressure and increase in the 
homogenization cycles the particle size was found to be 
decreasing.  
The value of correlation coefficient, R2 for particle size was 
found to be 0.9913 which indicated good fit of the model. 
 
Figure 3: Response surface plot showing influence of 
concentration of surfactant and homogenization 
pressure on particle size. 
 
Figure 4: Response surface plot showing influence of 
concentration of surfactant and homogenization cycle on 
Particle size. 
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Figure 5: Response surface plot showing influence of 
homogenization pressure and homogenization cycle on 
Particle size. 
3.6.2 Determination of Entrapment Efficiency: 
The %EE is the amount of drug trapped in SLN as against the 
amount which was added to the process. The %EE was found 
to range between 70 - 92.33%. There was a linear relation 
between all the factors and the decrease in entrapment.  
Equation 4 for Entrapment Efficiency: 
                                           
                                           
               2 
The model indicates that as the term A (concentration of 
tween 80) goes on decreasing the drug incorporation ability 
increases and thus the entrapment efficiency increases 
Equation (4).The high surfactant concentration causes large 
decrease in particle size and thus high interface for transfer 
of entrapped drug to dispersion medium resulting in 
decreased entrapment efficiency. The term B 
(homogenization pressure) had most dominant effect which 
is due to homogenizing valve under high density fluid-
dynamic energy conditions. It was observed that entrapment 
efficiency was not significantly affected by the Term C 
(homogenization cycles) but increasing number of 
homogenization cycles decreased entrapment efficiency due 
to the aggregation of particles. 
The interaction term AC i.e. the concentration of surfactant 
and homogenization cycle was seen to contribute reduction 
in drug entrapment which is because lower particle size of 
globules leading to enhanced area of migration of drug to 
aqueous phase.  
The interaction term AB i.e. concentration of surfactant and 
homogenization pressure led to mild increase in the 
entrapment efficiency due to contribution of pressure.  
The interaction term BC i.e. Entrapment efficiency was not 
highly affected by homogenization pressure and 
homogenization cycle. Similar effects were shown in figure 6 
and 7. 
The value of correlation coefficient, R2 for Entrapment 
efficiency was found to be 0.9876 which indicated good fit of 
the model. 
 
Figure 6: Response surface plot showing influence of 
concentration of surfactant and homogenization 
pressure on entrapment efficiency. 
 
Figure 7: Response surface plot showing influence of 
concentration of surfactant and homogenization cycle on 
entrapment efficiency. 
 
Figure 8: Response surface plot showing influence of 
homogenization pressure and homogenization cycle on 
entrapment efficiency. 
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The optimized batch was determined using desirability 
function, the criteria for optimization for particle size were 
to minimize and for EE it was to maximise. The solution 
obtained with highest desirability (0.98) was chosen which 
comprised 1% surfactant, homogenization pressure 1200 
and homogenization cycles 9. To evaluate the findings, 
verification run was carried out and no significant difference 
was found between the theoretical and the actual values of 
particle size and entrapment efficiency (Table 7). Thus the 
proposed model was seen to have high prognostic ability.
 
Table 7: Check Points for optimization, actual, predicted value and % error (n=3, Mean± SD) 
Formulation 
Code 
Composition of 
optimized 
formulation 
Response Predicted 
Value 
Actual Value % Error 
X1 X2 X3 
OF9 1 1200 9 Y1 239.66 nm 237 nm 2.66 
Y2 93.26% 91.33% 1.93 
 
The particle size of Blank SLN was found to be 200 nm. However, the zeta potential of Ginger extract solid lipid nanoparticles 
was seen to be slightly different to the Blank SLNs as seen in Table 8.  
Table 8: The particle size, zeta potential and entrapment efficiency of Blank Solid Lipid Nanoparticles and ginger 
extract Solid Lipid Nanoparticles are given in table. (n=3, Mean± SD) 
Formulation Particle Size 
(nm) 
Zeta Potential 
(mV) 
Polydispersity 
Index 
Entrapment 
Efficiency  
Blank SLNs 200 -32.8  0.286  --- 
[6]GE-SLNs 237 -25.3 0.350 91.33 
 
3.7 Differential Scanning Calorimetry (DSC): 
 
Figure 9: DSC thermograms of A]Stearic acid, B] (6)-Gingerol and C] (6)-Gingerol Solid Lipid Nanoparticles (GE-SLNs) 
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The melting endotherm of (6)-Gingerol and Stearic acid was 
observed at 40.20ºC and 70.91ºC respectively (Figure 8). 
The DSC thermograms of Solid Lipid Nanoparticles showed 
an endotherm at 68.20ºC this can be attributed to melting of 
Stearic acid in Solid Lipid Nanoparticles. This Shift of Solid 
Lipid Nanoparticles peak may be attributed to decrease in 
particle size and increase in the surface area. The endotherm 
of (6)-gingerol disappeared which indicates it is molecularly 
entrapped in stearic acid matrix.  
3.8 Ex-vivo Studies: 
The lymphatic uptake of nanoparticles involve numerous 
energy dependent processes of which primary are clathrin-
mediated endocytosis (receptor-mediated process), 
caveolae-mediated endocytosis (receptor-mediated process) 
and clathrin-caveolae independent process19. To 
demonstrate the existence of cellular uptake pathways for 
SLN, the experiment was carried out in the presence of 
inhibitors of clathrin as well as caveolae mediated 
endocytosis. Chlorpromazine, a cationic, amphiphilic drug, is 
reported to inhibit clathrin-mediated endocytosis by causing 
accumulation of clathrin in late endosomes thus reducing its 
availability on the enterocytes surface. The caveolae are 
special type of lipid rafts rich in cholesterol and sphingo 
lipids that are flask- shaped invagination on the plasma 
membrane to engulf cargo molecules or carriers binding to 
their surface. Antifungal drug nystatin is known to block the 
caveolae mediated uptake by cholesterol sequestration 
20,21,22. 
Figure 9 represents the apparent permeability of the (A) SLN 
containing Ginger extract at 37◦C, (B) SLN containing Ginger 
extract at 4◦C, (C) In presence of Chlorpromazine at 37◦C 
and (D) In presence of Nystatin at 37 ◦C measured at 30 
minutes. It was evident from the results that the apparent 
permeability in presence of Chlorpromazine was found to be 
15.83%. Similarly, the apparent permeability in presence of 
Nystatin was also found to be reduced to 20.8%, thus 
concluding the contribution of both clathrin and caveolae 
mediated process in the uptake of Solid Lipid Nanoparticles. 
After application of single way ANOVA followed by Turkey’s 
multiple comparison test, the difference between A, B, C, D 
was found significant (p < 0.001). The reduction in the 
apparent permeability at 4 °C to 8.2% in comparison with 
that at 37 °C also confirms the mechanism. 
 
Figure 9: Ex-vivo apparent permeability of SLN 
containing Ginger extract at A) SLN at 37◦C B) SLN at 
4◦C C) In presence of Chlorpromazine at 37◦C, D) In 
Presence of Nystatin at 37◦C 
4. CONCLUSION: 
The study investigated formulation optimization of DMARD 
(6)-Gingerol SLN for lymphatic uptake which can reduce 
side effects and improve concentration at inflamed site 
treatment of RA.  The study through ex vivo study using 
everted rat gut sac model established that SLN containing 
Ginger extract with particle size 237 nm and zeta potential -
25.3 mV of (6)-Gingerol SLN can effectively be taken up by 
lymphatic route, as demonstrated by lack of uptake in 
presence of lymphatic uptake blockers.  
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